Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus appointed BAP Pharma as its exclusive global partner to manage access programs for botensilimab and balstilimab, targeting authorized pathways like France’s AAC and paid named-patient programs. The partnership responds to significant demand, with Agenus citing over 270 physician inquiries from more than 30 countries seeking access to the therapies.
Key figures
- Countries
- more than 30
- Physician inquiries
- more than 270
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.